Source file signed link, expires in 15 minutes
Extracted text 13
Page 1
[Organon] Proprietary Public Expose PT Organon Pharma Indonesia, Tbk December 16 ,2024
Page 2
[Organon] Proprietary
Agenda
Business Organization Sustainability Financial
Overview Structure Strategy- ESG Performance
2
Page 3
[Organon] Proprietary
Business Overview
3
Page 4
[Organon] Proprietary
4
Page 5
[Organon] Proprietary
Business Overview – Areas of Focus
Women’s Established
Biosimilar
Health Brands
Through our pipeline and portfolio, Our approach to biosimilars is Our established brands span a
we are working to deliver medicines focused on providing more range of therapeutic areas,
and devices that advance the accessible treatment options to including cardiovascular disease,
health of women through all stages patients, providers, and healthcare respiratory conditions, dermatology,
of her life journey. We focus on systems central nervous system disorders,
conditions that are unique to bone health, immunology, non-
women, affect her opioid pain management,
disproportionately or impact her menopause, and more..
differently, including fertility and
contraception, maternal health
conditions, and vaginal health.
5
Page 6
[Organon] Proprietary
Organization Structure
Rapat Umum Pemegang Saham
General Meeting of Sharefolders
Dewan Komisaris Komite Audit
Board of Commissionaires Audit Committee
Presiden Komisaris Ketua Chairman :
President of Commissionaire Gideon Adi Siallagan
Andreas Daugaard Joergensen
Komisaris Komisaris Independen Anggota Members:
Commissionaire Independent Commissionaire • Sony Hutahaean
Erwin Agung Gideon Adi Siallagan • Ignatius Marthinus D
Direksi
Directors
Presiden Direktur Sekretaris Perusahaan
President Director Corporate Secretary
Daniel
Yuliana
Direktur Direktur Direktur
Director Director Director
Yuliana Andri Soelastyo Alison Yeap* *Sejak 16 Dec 2024 Since Dec 16th, 2024
6
Page 7
[Organon] Proprietary
ESG
Framework
7
Page 8
[Organon] Proprietary
Environmental Sustainability Goal
2050 ambitious environmental target
8
Page 9
[Organon] Proprietary
ENVIRONMENT Near-Term Goals and Long-Term Ambitions
GHG Emissions Water Materials
Integrate Circular Economy
Integrate Water Stewardship
Long- Term
Ambitions
principles into our business models
Net Zero Emissions principles into our business to maximize resource efficiency
models
• By 2025, we will reduce our Scope 1 and 2 • By 2025, we will reduce water usage in our • By 2025, >80% (range 80%-95%) of our
GHG emissions by >25% (range 25%- 40%) operations by >5% (range 5% -15%) from sites' operational waste will be reused,
from adjusted 2020* levels. adjusted 2020* levels. recycled or otherwise used beneficially.
• By 2023, we will characterize our Scope 3 • By 2023, we will characterize the water usage • By 2022, we will have developed Organon’s
Sustainability Packaging guidelines, which will
Near-Term Goals
emissions. of our value chain.
• By 2025, >70% (range 70% - 90%) of our • By 2025, >70% (range 70% - 90%) of our drive recycled content, recyclability, and
overall spending will be with suppliers that overall spending will be with suppliers that responsible sourcing.
have GHG emission reduction programs. have water reduction programs. • From 2023, the packaging of all new products
will be designed according to Organon’s
Sustainable Packaging guidelines.
• By 2025, 30% of Organon’s legacy packaging
will be reviewed against the Organon
Sustainable Packaging guidelines to identify
opportunities to reduce environmental impact.
*Baseline will be adjusted to normal (non-covid) circumstances
9
Page 10
[Organon] Proprietary
Page 11
[Organon] Proprietary
2024 Performance Highlight
11
Page 12
[Organon] Proprietary
2024 Financial Position (YTM Sep’24 vs 2023)
12
Page 13
Thank you
Names mentioned 1 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.